Xenetic Biosciences Inc (NASDAQ:XBIO)’s stock price was up 7.1% during trading on Thursday . The company traded as high as $1.72 and last traded at $1.66, approximately 475,982 shares traded hands during trading. An increase of 247% from the average daily volume of 137,300 shares. The stock had previously closed at $1.55.
The firm has a fifty day moving average of $1.98 and a 200-day moving average of $2.74.
An institutional investor recently raised its position in Xenetic Biosciences stock. Morgan Stanley increased its stake in Xenetic Biosciences Inc (NASDAQ:XBIO) by 1,050.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,082 shares of the company’s stock after purchasing an additional 32,945 shares during the period. Morgan Stanley owned 4.14% of Xenetic Biosciences worth $406,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.75% of the company’s stock.
Xenetic Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer.
Further Reading: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.